688266.SH
Suzhou Zelgen Biopharmaceuticals Co., Ltd.
SSE · Healthcare · Biotechnology · CN
CNY 117.83
−8.45%Sep 6, 2026, 07:32 UTC
Zelgen Biopharmaceuticals announced that its self-developed injection of human thyrotropin beta (brand: Zesuning) for a new indication has been accepted for marketing application review by China's National Medical Products Administration.
Source:Aug 18, 2026, 19:54 UTC
Zelgen Pharmaceuticals reported first-half 2026 revenue of 550 million yuan from four marketed innovative drugs, up 44.3% year-on-year.
Source:Aug 16, 2026, 13:57 UTC
Zelgen Biopharmaceuticals disclosed H1 revenue of 1.205 billion yuan, up 220.88% year-over-year, with net profit of 640 million yuan, turning from loss to profit.
Aug 16, 2026, 13:57 UTC
Zelgen Biopharmaceuticals reached a BD collaboration with AbbVie on ZG006, recognizing 662 million yuan in technology licensing revenue, with both parties accelerating global development.
Aug 12, 2026, 14:54 UTC
Suzhou Zelgen Biopharmaceuticals submitted a listing application to the Hong Kong Stock Exchange for an IPO, with CICC as the sole sponsor.